U.S. markets close in 4 hours 50 minutes
  • S&P 500

    4,641.32
    +74.32 (+1.63%)
     
  • Dow 30

    34,938.68
    +454.96 (+1.32%)
     
  • Nasdaq

    15,775.30
    +237.61 (+1.53%)
     
  • Russell 2000

    2,246.24
    +47.33 (+2.15%)
     
  • Crude Oil

    68.73
    +2.55 (+3.85%)
     
  • Gold

    1,788.20
    +11.70 (+0.66%)
     
  • Silver

    22.65
    -0.17 (-0.72%)
     
  • EUR/USD

    1.1333
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    1.4850
    +0.0420 (+2.91%)
     
  • GBP/USD

    1.3318
    +0.0017 (+0.13%)
     
  • USD/JPY

    113.0110
    -0.1690 (-0.15%)
     
  • BTC-USD

    58,833.52
    +1,628.77 (+2.85%)
     
  • CMC Crypto 200

    1,498.75
    +29.67 (+2.02%)
     
  • FTSE 100

    7,150.51
    +91.06 (+1.29%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Pawar Law Group Announces a Securities Class Action Lawsuit Against Cocrystal Pharma, Inc. – COCP

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and of Cocrystal's predecessor, BioZone, from September 23, 2013 through September 7, 2018, inclusive (the ''Class Period''). The lawsuit seeks to recover damages for Cocrystal investors under the federal securities laws.

To join the Cocrystal class action, go to http://pawarlawgroup.com/cases/cocrystal-pharma-inc/ or call Vik Pawar, Esq. at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal's stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants' statements about Cocrystal's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 19, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/cocrystal-pharma-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Contact:

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group